946525-30-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5-Iodobenzyl Alcohol serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to advancements in medicinal chemistry.
Used in Chemical Research:
In research labs, 2-Bromo-5-Iodobenzyl Alcohol is employed as a reactant or catalyst in various chemical reactions. Its distinct reactivity profile enables the exploration of novel chemical pathways and the synthesis of complex organic molecules.
Used in Agrochemical Industry:
2-Bromo-5-Iodobenzyl Alcohol is utilized as a component in the development of agrochemicals, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness and selectivity in controlling pests and weeds.
Used as Solvents:
Due to its solubility properties, 2-Bromo-5-Iodobenzyl Alcohol can be employed as a solvent in certain chemical processes. Its ability to dissolve a range of substances makes it a valuable asset in various industrial applications.
It is important to handle 2-Bromo-5-Iodobenzyl Alcohol with care due to its potential hazards and reactivity. Proper storage conditions are necessary to maintain its stability and ensure safe usage in various applications.

Upstream product

• 25252-00-0 2-bromo-5-iodobenzoic acid 
• 289617-98-7 2?bromo-4?iodobromomethylbenzene 
• 13194-68-8 4-iodo-2-methylaniline 
• 95-53-4 o-toluidine 
• 1032231-24-5 2-bromo-5-iodobenzaldehyde 
• 1261570-98-2 2-bromo-5-iodobenzoyl chloride 

Downstream Products

• 1539295-26-5 1-cyano-2-(4-cyclopropylbenzyl)-4-(β-D-glucopyranos-1-yl)benzene L-proline 
• 946525-35-5 1-bromo-4-(2,3,4,6-tetra-O-acetyl-1-deoxy-D-glucopyranos-1-yl)-2-(phenoxymethyl)-benzene 
• 946525-36-6 2-(phenoxymethyl)-4-(2,3,4,6-tetra-O-acetyl-1-deoxy-D-glucopyranos-1-yl)-benzonitrile 
• 946525-37-7 2-bromomethyl-4-(2,3,4,6-tetra-O-acetyl-1-deoxy-D-glucopyranos-1-yl)-benzonitrile 
• 1378427-96-3 5-cyclopropyl-2-(4-fluorophenyl)-6-(N-(2-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)ethyl)methylsulfonamido)-N-methylbenzofuran-3-carboxamide 
• 1378465-81-6 6-(N-(3-((tert-butyldimethylsilyloxy)methyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide 
• 1378431-50-5 6-(N-(4-bromo-3-((tert-butyldimethylsilyloxy)methyl)phenethyl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide 
• 1378431-49-2 (2-bromo-5-(2-bromoethyl)benzyloxy)(tert-butyl)dimethylsilane 
• 1378431-48-1 2-(4-bromo-3-((tert-butyldimethylsilyloxy)methyl)phenyl)ethanol 
• 1378431-47-0 (5-allyl-2-bromobenzyloxy)(tert-butyl)dimethylsilane 
• 1378382-90-1 (2-bromo-5-iodobenzyloxy)(tert-butyl)dimethylsilane 
• 946525-31-1 4-bromo-3-chloromethyl-1-iodo-benzene 

Relevant academic research and scientific papers

Preparation method of 2-bromo-5-iodo-benzyl alcohol

The invention relates to the technical field of organic synthesis, and discloses a preparation method of 2-bromine-5-iodine-benzyl alcohol, which comprises the following steps: S1, o-benzylamine, a phase transfer catalyst, ammonium bicarbonate and an iodination reagent are subjected to iodination reaction to generate 2-methyl-4-iodoaniline; S2, the 2-methyl-4-iodoaniline is subjected to a diazotization reaction and a bromination reaction, and 2-bromine-4-iodobenzene is generated; S3, the 2-bromine-4-iodobenzene reacts with an initiator and N-bromosuccinimide, so as to generate 2-bromine-4-iodobromomethyl benzene; and S4, the 2-bromine-4-iodine bromomethyl benzene reacts with alkali, so as to generate the 2-bromine-5-iodine-benzyl alcohol. The preparation method disclosed by the invention is simple in process operation, few in three wastes and beneficial to industrial production; and no isomer is generated in the iodinated product, reduction of lithium aluminum hydride is not needed, and the problem of high operation risk caused by a large amount of hydrogen generated during reduction of lithium aluminum hydride can be effectively avoided.

Preparation method of 2-bromo-5-iodobenzyl alcohol

The invention discloses a preparation method of 2-bromo-5-iodobenzyl alcohol. A synthesis route is simple and typical, and is simple and convenient to operate, the yield of target products is high, 1,3-diiodo-5,5-dimethyl hydantoin as an iodization reagen

BICYCLIC PROLINE COMPOUNDS

The invention is concerned with the compounds of formula (I) and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more sele

TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more sele

TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more sele

TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.

CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(SS- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS

The invention relates to a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D-glucopyranos-1-yl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments.

CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(?- D-GLUCOPYRANOS-1-YL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS

The invention relates to a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(β-D- glucopyranos-1 -yl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments.

TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS

The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a ph